Volume 4 Issue 2
Apr.  2013
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2013.02.021
  • Received Date: 2013-02-28
  • Publish Date: 2013-04-30
  • loading
  • [1] Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group[J]. Arch Ophthalmol, 1985, 103: 1796-1806.
    [2] Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema[J]. Ophthalmology, 2008, 115:1447-1459. doi:  10.1016/j.ophtha.2008.06.015
    [3] Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases?[J]. Am J Ophthalmol, 2011, 152:332-339. doi:  10.1016/j.ajo.2011.04.015
    [4] Cardillo JA, Melo LAS, Costa RA, et al. Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema[J]. Ophthalmology, 2005, 112:1557-1563. doi:  10.1016/j.ophtha.2005.03.023
    [5] Takata C, Messias A, Folgosa MS, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema[J]. Retina, 2010, 30:562-569. doi:  10.1097/IAE.0b013e3181c969b4
    [6] Bonini MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refr actory diabetic macular edema:a randomized clinical trial[J]. Invest Ophthalmol Vis Sci, 2005, 46:3845-3849. doi:  10.1167/iovs.05-0297
    [7] Choi YJ, Oh IK, Oh JR, et al. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema[J]. Korean J Ophthalmol, 2006, 20:205-209. doi:  10.3341/kjo.2006.20.4.205
    [8] Yalcinbayir O, Gelisken O, Kaderli B, et al. Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffu se diabetic macular edema[J]. Ophthalmologica, 2011, 225:222-227. doi:  10.1159/000324714
    [9] Qi HP, Bi S, Wei SQ, et al. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema:a systematic review and Meta-analysis[J]. Curr Eye Res, 2012, 37:1136-1147. doi:  10.3109/02713683.2012.705412
    [10] Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy[J]. Arch Ophthalmol, 2006, 124:643-650. doi:  10.1001/archopht.124.5.643
    [11] Choi KS, Chung JK, Lim SH. Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema[J]. Korean J Ophthalmol, 2007, 21:11-17. doi:  10.3341/kjo.2007.21.1.11
    [12] Maia OO Jr, Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema:one-year results of a randomized clinical trial[J]. Am J Ophthalmol, 2009, 147:291-297. doi:  10.1016/j.ajo.2008.08.024
    [13] Mirshahi A, Shenazandi H, Lashay A, et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema[J]. Retina, 2010, 30:254-259. doi:  10.1097/IAE.0b013e3181b4f125
    [14] Liu L, Wu X, Geng J, et al. IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema:a meta-analysis[J]. PLoS One, 2012, 7:e44683. doi:  10.1371/journal.pone.0044683
    [15] Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J]. Diabetes Care, 2010, 33:2399-2405. doi:  10.2337/dc10-0493
    [16] Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118:615-625. doi:  10.1016/j.ophtha.2011.01.031
    [17] Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema:a placebo-controlled, randomized clinical trial[J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246:483-489. doi:  10.1007/s00417-007-0688-0
    [18] Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12month data:report 2[J]. Ophthalmology, 2010, 117:10781086. https://pubmed.ncbi.nlm.nih.gov/20416952/
    [19] Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema[J]. Ophthalmology, 2009, 116:1142-1150. doi:  10.1016/j.ophtha.2009.01.011
    [20] Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema[J]. Retina, 2010, 30:1638-1645. doi:  10.1097/IAE.0b013e3181e1ed07
    [21] Zechmeister-Koss I, Huić M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema:a systematic review[J]. Br J Ophthalmol, 2012, 96:167-178. doi:  10.1136/bjophthalmol-2011-300674
    [22] Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)[J]. Br J Ophthalmol, 2008, 92:76-80. doi:  10.1136/bjo.2007.129122
    [23] Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2010, 117:1064-1077. doi:  10.1016/j.ophtha.2010.02.031
    [24] Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study[J]. Ophthalmology, 2009, 116:2175-2181. doi:  10.1016/j.ophtha.2009.04.023
    [25] Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2011, 118:609-614. doi:  10.1016/j.ophtha.2010.12.033
    [26] Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumabaugmented retinal laser photocoagulation in proliferative diabetic retinopathy:a randomized double-masked clinical trial[J]. Eur J Ophthalmol, 2008, 18:263-269. doi:  10.1177/112067210801800215
    [27] Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2011, 89:e567-e572. doi:  10.1111/j.1755-3768.2011.02184.x
    [28] Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy[J]. Retina, 2009, 29:516-522. doi:  10.1097/IAE.0b013e31819a5fc2
    [29] Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)[J]. Retina, 2006, 26:1006-1013. doi:  10.1097/01.iae.0000246884.76018.63
    [30] Erdol H, Turk A, Akyol NN, et al. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy[J]. Retina, 2010, 30:570-577. doi:  10.1097/IAE.0b013e3181bf5ff0
    [31] Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for highrisk proliferative diabetic retinopathy (IBeHi study)[J]. Acta Ophthalmol, 2008, 86:385-389. doi:  10.1111/j.1600-0420.2007.01056.x
    [32] Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage[J]. Retina, 2009, 29:1134-1140. doi:  10.1097/IAE.0b013e3181b094b7
    [33] Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246:1699-1705. doi:  10.1007/s00417-008-0914-4
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (137) PDF downloads(21) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return